News

The new guidance is the first update since 2008, replacing the previous risk-based recommendations.

New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.

New data demonstrated that the combined use of prednisone and methotrexate saw positive results in hair regrowth for patients with alopecia totalis or alopecia universalis.

Neutropenia, male gender, high serum creatinine, and albumin were all associated with fatal outcomes.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.

Gregg W. Stone, MD, discussed the 5-year findings of the COAPT trial and provided insight into the benefit of the transcatheter procedure in high-risk patients with heart failure.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

An analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials provides insight into the atherosclerotic cardiovascular risk associated with high-sensitivity C-reactive protein.

Although etanercept biosimilars demonstrated comparable efficacy, safety, and immunogenicity when compared with the reference drug, biosimilar treatment was associated with a better ACR50 response rate.

Viet Le, PA-C, offers perspective on a study from Intermountain Healthcare reporting on the epidemiology, relationship to ASCVD risk factors, and clinical outcomes associated with Lp(a) in real-world settings.

In a research letter, patient perspectives were explored regarding access to dermatology clinic notes, with more than half reporting improved understanding due to notes.

There were increases in fibrosis stage for 24% of patients in the rifaximin-α group, compared to 43% of the placebo group.

In another interview segment, Castells discussed the safety profile of avapritinib for indolent systemic mastocytosis, as well as future research.

A new study from China shows predictive value of baseline PCV presence and PED characteristics among patients with nAMD receiving conbercept.

There was a 0.9% increase in the first dispensation of infliximab, either the biosimilar or originator during the first year of follow-up, as well as a 16.2% increase in infliximab dose escalation, a 2.4% decrease in the dispensation of antibiotics, and a 2.6% decrease in the new use of prednisone.

Research indicates that a potential reduction in healthcare costs could result from utilization of biosimilars for adalimumab and etanercept in dermatology.

The odds of hospitalizations with acetaminophen and opioid toxicity increased by 11% per year prior to the mandate and decreased by 11% per year after the announcement.

In another interview segment, Castells went further into depth regarding the PIONEER trial results and regarding avapritinib’s effect on mastocytosis.

Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.

Deepak Bhatt, MD, MPH, discusses results of the phase 2 ENTRIGUE trial and how it informs clinicians on the effects of the human FGF21 analogue in patients with severe hypertriglyceridemia.

If approved, Boehringer Ingelheim and Eli Lilly and Company's SGLT2 inhibitor would be the first agent in the class with an indication as an adjunct to diet and exercise for improving glycemic control in children with type 2 diabetes aged 10 years and older.

The results show 58% of patients treated with ustekinumab were in clinical remission, while 80% were in clinical response.

New data from AAAAI was described by Castells, who explained some of the background of the recent PIONEER trial on avapritinib for mastocytosis patients.

New research from a phase 2b trial presented at ACC 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular disease.

A one-of-its-kind assessment of 8 decades' worth of UK data show a lower respiratory tract infection by age 2 increases risk of premature adult death by 93%.

Hear from Deepak Bhatt, MD, MPH, as he discusses how he interprets the results of the HALO trial and offers perspective on the forthcoming research related to baxdrostat.

Novan announced on Tuesday that the FDA accepted the New Drug Application (NDA) for Berdazimer Gel, a topical antiviral molluscum contagiosum treatment, for review.

A new study supports an individualized treatment plan for aflibercept, showing its improved efficacy with fewer injections over 2 years.